45 results about "Symbiotic bacteria" patented technology

The invention discloses a co-fermentation method based on sphingomonas and a rhodiola rosea extracting solution and application of a product, and belongs to the technical field of microorganisms. By utilizing a special rich enzyme system of sphingomonas and combining with an early-stage composite enzymolysis process and synergistic effect, the wall breaking efficiency of rhodiola rosea cell walls and the conversion degree of active components of rhodiola rosea are greatly improved, the bottlenecks of low efficiency and low bioavailability of a traditional rhodiola rosea extraction method are successfully overcome, and the rhodiola rosea extraction method is suitable for industrial production. The functional components such as salidroside and flavone can be fully released and converted. Secondly, different from non-symbiotic bacteria (such as lactic acid bacteria and saccharomycetes) which are commonly used for fermentation in the prior art, a potential symbiotic bacterium of sphingomonas XJL-TP07 from a special environment is innovatively selected and has better metabolic suitability with the rhodiola rosea component, the fermentation process is milder and safer (no irritant is produced), and the rhodiola rosea fermentation method is suitable for large-scale production. And a synergistic interaction effect can be generated through a unique biotransformation path.

Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.

The present application relates to the field of microorganism, specifically to three strains of Acrocalymma sp. symbiotic bacteria E00677, E01299A and E01299B and their use for tomato growth. The strains of the present application can promote tomato growth, improve tomato leaf quality, and enhance the antioxidant and stress resistance of tomato.

The invention discloses an intestinal symbiotic bacterium for enhancing baculovirus resistance of spodoptera frugiperda and application thereof, and relates to the technical field of microorganisms, the intestinal symbiotic bacterium is derived from the midgut of the spodoptera frugiperda, is separated and purified and is subjected to 16S rDNA (ribosomal deoxyribonucleic acid) gene sequencing identification, the sequence length is 1397 bp, and the sequence homology with the known Glutamicibacter soli is 99.93%. The strain is preserved in Institute of Microbiology, Chinese Academy of Sciences, and the preservation number is CGMCC No.34972. The invention provides intestinal symbiotic bacteria for enhancing baculovirus resistance of spodoptera frugiperda and application of the intestinal symbiotic bacteria, and provides an experimental basis for further revealing an interaction mechanism among a host, a pathogen and the symbiotic bacteria. And meanwhile, a technical basis is provided for realizing a comprehensive virus prevention and control strategy of targeted biological prevention and control and non-target beneficial insect protection of the lepidoptera pests.

This invention provides the application of Lycium barbarum polysaccharide (LBP) in the preparation of drugs for the prevention or treatment of intestinal flora and metabolic disorders. Research results show that LBP can significantly improve cisplatin-induced intestinal microbiota and metabolic disorders in rats, manifested by a significant reduction in CDDP-induced serum AST and ALT levels, and improvement in the degree of liver tissue lesions. Furthermore, LBP did not exhibit toxicity in rats. LBP enhanced the diversity and richness of the gut microbiota, restored the structure of dominant symbiotic bacteria, inhibited the proliferation of potentially pathogenic bacteria, and promoted the enrichment of functional bacteria related to SCFAs generation. LBP also restored abnormal metabolism in branched-chain amino acid and aromatic amino acid metabolism, one-carbon metabolism, and lipid metabolism. This invention provides a theoretical basis for the application of natural active polysaccharides in the prevention and treatment of intestinal microbiota and metabolic disorders.

The invention belongs to the technical field of orchid seedling culture, and discloses orchid seed matrix particles for field direct seeding and a preparation method, and the matrix particles comprise coco coir powder, peat soil, a porous inorganic matrix, a degradable adhesive, a bio-organic fertilizer, symbiotic bacteria, orchid seeds and water. The matrix particles adopt a core-shell structure, the core contains seeds, symbiotic bacteria and the like for water retention and moisture retention, and the shell is a porous inorganic matrix and the like for guaranteeing ventilation and mechanical strength. The granules can be directly sown in a field, do not need laboratory seedling culture, can realize high-efficiency seed germination and in-situ mycorrhiza colonization, has the seedling rate close to that of traditional sterile seedling transplantation, reduces labor and facility investment, reduces the disease risk, and is suitable for large-scale planting of orchid plants such as bletilla striata and dendrobe.

The invention relates to an armillaria mellea rhizomorph generation and biomass increasing method based on plant hormone regulation and control, the growth promoting effect of low-concentration 0.1 mg / LZR and / or ET on armillaria mellea is determined for the first time, the traditional cognition that high-concentration hormone inhibits growth is broken through, and the problem that in the prior art, the hormone concentration is difficult to control is solved. The combined use of the ZR and the ET can synchronously optimize the diameter, the number of branches and the biomass of the chords, the comprehensive effect is superior to that of a single hormone, and a new strategy is provided for efficient culture of the armillaria mellea. The method is suitable for liquid fermentation and solid culture, the culture period is short (15-16 days), the production cost of gastrodia elata symbiotic bacteria and medicinal mycelia can be remarkably reduced, and large-scale popularization is easy.

The invention relates to the technical field of secondary metabolite retrieval, and discloses a microorganism secondary metabolite retrieval method based on a knowledge graph, the method is applied to retrieval of alternative items of symbiotic bacteria of valuable and rare medicinal plants, and the method comprises the steps that a retrieval knowledge graph is constructed, key features serve as input, and microorganisms corresponding to the key features are output; performing feature transformation processing to obtain potential substitutes of the key features as to-be-selected transformation features; and based on the to-be-selected transformation features, performing retrieval in the retrieval knowledge graph at least based on the similarity and the attention weight, and outputting alternative items of microorganisms corresponding to the target secondary metabolite. According to the application, dependence on symbiotic bacteria of rare medicinal plants is eliminated, adaptive microorganism substitutes of target secondary metabolites are quickly locked, and the research period is greatly shortened; the screening range of microbial substitutes is widened, the missing of effective strains is reduced, and sufficient strain resource support is provided for large-scale production of medicinal active compounds.

A strain of Dubois nystomatitis ( Dubosiella newyorkensis TZF-002 and its application in the fermentation and conversion of rare ginsenosides belong to the field of microbiology. The *Duboscirella nymphaeus* mentioned herein (…) Dubosiella newyorkensis TZF-002 was deposited at the China Center for Type Culture Collection on December 15, 2025, with accession number CCTCC NO: M 20252890. This invention uses total ginsenosides as raw material, first utilizing the high-β-glucosidase-producing *Duboscirella nystatin* (…). Dubosiella newyorkensis The TZF-002 method employs a mild and controlled fermentation process to transform primary ginsenosides, followed by high-temperature steam treatment, ultimately yielding rare ginsenosides Rg6, F4, Rh4, S-Rg3, R-Rg3, Rk1, and Rg5 efficiently. This method, for the first time, combines the enzymatic transformation characteristics of intestinal symbiotic bacteria with physical treatment, offering advantages such as mild conditions, low cost, and significantly superior product variety and content compared to single processes. It effectively improves the yield, bioavailability, and physiological activity of rare saponins.

The present application relates to biopharmaceutical manufacturing, more particularly to the field of penetration enhancers, and specifically discloses a transdermal absorption penetration enhancer, a preparation method thereof and application in cosmetics. The penetration enhancer comprises plant exosomes, natural penetration activity molecules, film forming agents, ZIF-90 nanomaterials, temperature / ROS dual response ion channel regulating molecules and skin symbiotic bacteria activating materials. The preparation method comprises the steps of plant exosome extraction, hydrophobic / hydrophilic active molecule encapsulation, ZIF-90 nanoshell growth, ion channel regulating molecule anchoring, introduction of skin symbiotic bacteria activating materials, addition of film forming agents, ultrafiltration centrifugal concentration and sterilization filling and the like. Through the triple synergy of plant exosome-ZIF-90 nanocore-shell structure, temperature / ROS dual response regulation and skin symbiotic bacteria activation, the present application realizes efficient, low irritation and intelligent controllable transdermal delivery of active substances, and is suitable for various cosmetic dosage forms.

The application discloses a kind of complex small molecule coral food and its application in adjusting coral symbiotic microbial community structure.The raw materials of the complex small molecule coral food include: soybean meal small peptide protein, cod small peptide protein, haematococcus pluvialis powder, complex amino acid, squid meal, chitosan oligosaccharide and complex nucleotide.The complex small molecule coral food of the application takes soybean meal small peptide protein and cod small peptide protein as main component, haematococcus pluvialis as secondary component, and is supplemented with complex amino acid and squid meal, and is additionally added with chitosan oligosaccharide and complex nucleotide.The obtained complex small molecule coral food not only has good palatability, but also ensures the feeding amount of coral.It is verified by test that the complex small molecule coral food of the application can adjust the symbiotic microbial community structure of aquarium coral, improve the proportion of coral beneficial symbiotic bacteria, and further improve the environmental tolerance of coral.

The invention belongs to the technical field of microbial genetic engineering and protein delivery, and particularly relates to an engineered bacterial secretion system for efficiently delivering protein and application of the engineered bacterial secretion system. Specifically, on the basis of analyzing a delivery mechanism of bacteroides fragilis GS086 type double-effect protein T6SS, engineering modification is performed on a toxic structural domain of the effect protein, and a bacterial secretion system capable of efficiently and simultaneously delivering a plurality of proteins is constructed. According to the system, a modified strain is a natural human intestinal symbiotic bacterium, the problems of high immunogenicity, poor stability and the like are effectively avoided, and protein can be delivered in situ in the intestinal tract to realize precise regulation and control of an intestinal flora structure and secretion of specific target protein, so that the system has a good practical application value.

This invention relates to an antitumor agent based on respiratory tract symbiotic bacteria, its preparation method, and its application. Addressing the current clinical issue of the unclear role of respiratory flora in lung cancer patients' progression, we provide the first evidence that the respiratory tract symbiotic *Streptococcus osticulata* possesses antitumor activity. When *Streptococcus osticulata* is delivered back into the respiratory tract, it can stimulate an antitumor immune response, and its efficacy can be further enhanced by adenosylcobalamin. Currently, there is a lack of non-invasive, non-invasive inhaled treatments for lung cancer. The antitumor agent of this invention can be combined with novel non-invasive inhaled bacterial-metabolite immunotherapy to achieve a long-term chronic disease management model, representing a safe and transferable treatment approach. In addition to achieving effective lung tumor control when used alone, this therapy can synergistically enhance the efficacy of immunotherapy, inducing complete tumor regression in 50% of tumor-bearing mice.

This invention discloses the application of an artemisia annua compound as the sole active ingredient in the preparation of topical formulations for the prevention or improvement of blackheads and acne. Based on 100% of the total mass of the topical formulation, the artemisia annua compound accounts for 0.1% to 0.22%, and is composed of the following raw materials in parts by mass: camphene 4 to 10 parts, artemisinin 1 part. This invention also discloses a topical formulation for the prevention or improvement of blackheads and acne, the sole active ingredient of which is an artemisia annua compound. Based on 100% of the total mass of the topical formulation, the artemisia annua compound accounts for 0.1% to 0.22%, and is composed of the following raw materials in parts by mass: camphene 4 to 10 parts, artemisinin 1 part. The artemisia annua compound of this invention can significantly reduce the formation of squalene peroxide in a UVA-induced squalene photo-oxidation model, and shows stronger inhibition against Malassezia and less impact on Staphylococcus epidermidis in a Malassezia vs. symbiotic bacteria comparison model.

The invention provides application of parabacteroides dieldrii in preparation of a medicine for treating Parkinson's disease. The parabacteroides dieldrii can play a neuroprotective role through multiple mechanisms of regulating intestinal flora, reducing neuroinflammation, improving a blood-brain barrier function and the like. Animal experiments show that the active parabacteroides dielsii can significantly improve PD mouse dyskinesia, protect dopaminergic neurons, repair intestinal and central barriers, and remodel a metabolite spectrum related to nerve regulation. The intestinal symbiotic bacterium parabacteroides dieldrii provided by the invention has a good effect of treating the Parkinson's disease, and has a wide application prospect in the field of micro-ecological treatment of the Parkinson's disease.

The invention discloses a flora-friendly selective antifungal peptide RVH and application thereof, and belongs to the technical field of novel antibacterial materials. The antifungal peptide RVH can resist pathogenic fungi on the premise of maintaining flora balance, drug resistance is not prone to being generated, the antifungal peptide RVH has high biological safety and has a certain inhibition effect on matrix metalloproteinase, and more importantly, the antifungal peptide RVH only selectively resists pathogenic fungi instead of bacteria, and especially does not resist symbiotic bacteria.

The invention relates to biological medicine manufacturing, in particular to the field of penetration enhancers, and particularly discloses a transdermal absorption penetration enhancer, a preparation method thereof and application of the transdermal absorption penetration enhancer in cosmetics. The penetration enhancer comprises a plant exosome, a natural penetration enhancing active molecule, a film-forming agent, a ZIF-90 nano material, a temperature / ROS dual-response ion channel regulation molecule and a skin symbiotic bacterium activation material. The preparation method comprises the steps of plant exosome extraction, hydrophobic / hydrophilic active molecule entrapment, ZIF-90 nanometer shell growth, ion channel regulation molecule anchoring, skin symbiotic bacterium activation material introduction, film-forming agent addition, ultrafiltration centrifugal concentration, degerming filling and the like. Through triple synergy of a plant exosome-ZIF-90 nano core-shell structure, temperature / ROS dual-response regulation and skin symbiotic bacteria activation, efficient, low-irritation, intelligent and controllable transdermal delivery of active matters is realized, and the preparation method is suitable for various cosmetic dosage forms.

The invention relates to the technical field of feed additives, in particular to a feed additive for preventing goose gout based on bacterium-enzyme synergistic targeted release as well as a preparation method and application of the feed additive. The invention provides a feed additive for preventing goose gout based on bacterium-enzyme synergistic targeted release, which comprises the following components in parts by weight: 5-10 parts of enveloped tributyrin and 5-10 parts of an enzyme-producing symbiotic bacterium composition, the enzyme-producing symbiotic bacterium composition comprises a fermented product obtained by carrying out symbiotic fermentation on pediococcus pentosaceus SMM914 and bacillus subtilis. In the formula of the feed additive, the slow-release characteristic of the enveloped tributyrin is utilized to ensure that the enveloped tributyrin and the enzyme-producing symbiotic bacterium compound synchronously reach the rear section of the intestinal tract, the butyric acid is efficiently utilized, targeted positioning release is realized, and the butyric acid can be continuously released to achieve a stable relieving or treating effect.

The invention discloses Dubosiella Newyorkens TZF-002 and an application of the Dubosiella Newyorkens TZF-002 in preparation of rare ginsenoside through fermentation conversion, and belongs to the field of microorganisms. The Dubosiella Newyorkens TZF-002 is preserved in the China Center for Type Culture Collection on December 15, 2025, and the preservation number of the Dubosiella Newyorkens TZF-002 is CCTCC (China Center for Type Culture Collection) NO: M 20252890. The preparation method comprises the following steps: by taking total ginsenoside of ginseng as a raw material, firstly, carrying out mild and controllable fermentation conversion on primary ginsenoside by utilizing Dubosiella Newyorkens TZF-002 capable of producing beta-glucosidase at high yield, and finally, efficiently preparing rare ginsenoside Rg6, F4, Rh4, S-Rg3, R-Rg3, Rk1 and Rg5 in combination with high-temperature steam treatment, so as to obtain the rare ginsenoside Rg6, F4, Rh4, S-Rg3, R-Rg3, Rk1 and Rg5. According to the method, the enzymatic conversion characteristic of the intestinal symbiotic bacteria is combined with physical treatment for the first time, the method has the advantages of mild conditions, low cost, obviously better product variety and content than a single process and the like, and the yield, bioavailability and physiological activity of the rare saponin can be effectively improved.

The invention provides an antibacterial peptide as well as a screening method and application thereof. On the first aspect, the invention provides the antibacterial peptide, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO. 1. The antibacterial peptide has high specificity on staphylococcus aureus in a certain concentration range, has no inhibition effect on other common skin symbiotic bacteria such as staphylococcus epidermidis, staphylococcus vorus and propionibacterium acnes, can avoid damage to normal flora balance of a human body, reduces the risk of secondary infection, and has a good application prospect. The problem of flora imbalance caused by broad-spectrum killing of the existing antibacterial peptide is solved. In addition, the minimum inhibitory concentration on staphylococcus aureus is low, the obvious bacteriostatic effect can be achieved under the condition of lower dosage, and the medicine dosage and potential side effects are reduced. In addition, the compound is derived from human skin symbiotic microorganisms and has good biocompatibility with the human body, in-vitro cytotoxicity experiments prove that the effective antibacterial concentration of the compound has no obvious toxicity on human skin keratinocytes, and the safety of the compound is superior to that of chemically synthesized antibacterial molecules.

The invention provides a novel application of an antibacterial peptide Ly (PEG)-1 reported at an earlier stage in vaginitis, belongs to the technical field of biomedical polypeptides, and particularly relates to preparation of the antibacterial peptide Ly (PEG)-1, an effect of the antibacterial peptide Ly (PEG)-1 on main vaginal pathogenic bacteria and symbiotic bacteria and an application of the antibacterial peptide Ly (PEG)-1 in prevention or treatment of bacterial vaginitis. The antibacterial peptide Ly (PEG)-1 provided by the invention is short in sequence, low in production cost, capable of strongly inhibiting main pathogenic bacteria of vagina, small in influence on main normal bacteria of the main pathogenic bacteria, capable of effectively treating vagina inflammation and maintaining the steady state of vaginal flora, high in stability and good in antibacterial effect. Vagina inflammatory diseases caused by infection of various pathogenic bacteria can be prevented and treated through various administration modes such as spraying, instillation, suppositories and effervescent tablets or systemic administration modes such as intraperitoneal injection and the like.

The invention relates to the technical field of biology, in particular to a cellulase technology in the field of enzymology. The invention relates to the technical field of cellulose degradation, in particular to application of a GH5GH6 double-catalytic structural domain compound enzyme (containing a glycoside hydrolase family 5 (GH5) and a glycoside hydrolase family 6 (GH6)) in cellulose degradation. The invention relates to an application of a GH5GH6 double-catalytic structural domain compound enzyme in cellulose degradation. The GH5GH6 double-catalytic structural domain compound enzyme is derived from ship maggot symbiotic bacteria. The ship maggot symbiotic bacterium is a known strain Teredinibacter species, in particular to a Teredinibacter Turnerae strain, and the ship maggot symbiotic bacterium can be used for preparing the ship maggot symbiotic bacterium. According to the invention, a multifunctional enzyme compound catalyzed by double structural domains of GH5 and GH6 is obtained from a ship maggot symbiotic bacterium Teredinibacter, the compound is formed by arranging and connecting the GH5, the GH6 and 2-4 CBMs, three different functional structural domains of the GH5, the CBMs and the GH6 are integrated, and the efficiency and the stability of cellulose degradation are remarkably improved.

Provided herein are devices, systems, kits, and methods for sampling air and / or a surface in an enclosed space (e.g., hospital, clinic room, daycare room, classroom, workspace, or factory) with an assay for at least one human commensal bacterial and / or viral nucleic acid sequence normally present in the respiratory track and / or oral cavity of human, such that such assay serves as a proxy for detecting at least one human respiratory pathogen (which can be very hard to detect in such spaces as they can be at very low levels and still be relevant). Such commensal bacterial and / or viral nucleic acid detection can inform actions such as moving a patient into the enclosed space or taking actions to kill or remove microorganisms in the enclosed space (e.g., replacing HVAC filter that feeds into the enclosed space). Such commensal bacterial and or viral nucleic acid detection can serve as a proxy for how well the action to kill or remove pathogens is performing.

The application discloses a waxberry CRRSP1 gene and application thereof, and belongs to the technical field of genetic engineering. The application provides a CRRSP1 gene which is specifically up-regulated in the root nodule of a waxberry, and the CDS sequence of the CRRSP1 gene is shown as SEQ ID NO. 1. The application also provides application of the waxberry CRRSP1 gene in promoting symbiotic interaction between a nodule plant and symbiotic bacteria, and the application comprises: up-regulating expression of the waxberry CRRSP1 gene in the nodule plant by using a biological technical means. By up-regulating expression of the gene in the nodule plant, symbiotic nodulation of the nodule plant and the symbiotic bacteria can be significantly promoted, and the plant biomass is increased. The application provides an important reference value for research on symbiotic genes.

The invention discloses a flora-friendly selective antifungal peptide HRF and application thereof, and belongs to the technical field of novel antibacterial materials. The antifungal peptide HRF provided by the invention can only selectively resist pathogenic fungi but not resist bacteria, especially does not resist symbiotic bacteria, has relatively high biological safety, and has a certain inhibition effect on matrix metalloproteinase (MMP-9).

The invention relates to an anti-tumor preparation based on respiratory tract symbiotic bacteria as well as a preparation method and application thereof, and provides evidence for the first time aiming at the problem that the respiratory tract flora of a lung cancer patient is not exact in lung cancer progression clinically at present, and the evidence shows that the respiratory tract symbiotic bacteria oral streptococcus has an anti-tumor effect; when the oral streptococcus is delivered back to the respiratory tract, the anti-tumor immune response can be stimulated, and the curative effect of the oral streptococcus can be further enhanced through cobamamide. At present, a non-invasive and non-invasive inhalation type treatment mode for treating lung cancer is lacked clinically, and the anti-tumor preparation can be combined with a novel non-invasive inhalation type bacterium-metabolite immunotherapy to realize a long-term chronic disease management mode, and is a safe and convertible treatment means. On the basis that effective lung tumor control can be realized through independent use, the therapy can synergistically enhance the curative effect of immunotherapy, and tumors are induced to completely subside on 50% of tumor-bearing mice.

The application discloses application of a liquid fermentation product of a cryptoporus symbiotic bacteria in preparation of an anticancer drug and belongs to the technical field of cell biology. The cryptoporus symbiotic bacteria is Trichoderma stromaticum, which was preserved in the China General Microbiological Culture Collection Center on November 8, 2023, has a preservation number of CGMCC No. 40914 and a preservation address of No. 3, Institute of Microbiology, Chinese Academy of Sciences, Xiliujiaobei, Chaoyang District, Beijing. The liquid fermentation product of the cryptoporus symbiotic bacteria provided in the application has good biological activity, can inhibit the growth of tumors and has a good anticancer effect on lung cancer cells. The application provides a theoretical basis for the liquid fermentation product of the cryptoporus symbiotic bacteria as an antitumor drug.

The invention relates to the technical field of biological enzymes, and discloses an N-acyl homoserine lactone degrading enzyme as well as a preparation method and application thereof. Wherein the amino acid sequence of the N-acyl homoserine lactone degrading enzyme is as shown in SEQ ID NO. 1. The N-acyl homoserine lactone degrading enzyme disclosed by the invention is derived from a co-epiphytic bacterium Pseudomonas onchidi XY-99 of a marine invertebrate organism, i.e., calf stone, has wide signal molecule degradation activity, can block a quorum sensing pathway of pathogenic bacteria and inhibit the generation of virulence factors and the formation of a biofilm, and can be used for preparing a product for preventing and controlling pseudomonas aeruginosa.

The invention belongs to the technical field of biology and medicine, and discloses a microcolony-based 3D simulated human skin model, a preparation method and application, and the preparation method comprises the following steps: preparing the 3D simulated human skin model; preparing to obtain the fungus-coated micro-capsule; and paving the microencapsulated microcapsules on the surface of the 3D simulated human skin model to obtain the microcolony-based 3D simulated human skin model. On the basis of a traditional 3D skin model, common skin symbiotic bacteria are wrapped in the microcapsules formed by cross-linking CS and TPP, direct contact between bacteria and between bacteria and the skin model is avoided due to existence of the microcapsules, bacterial secretions can be diffused out of the microcapsules through micropores in the surfaces of the microcapsules, material exchange with the outside is achieved, and the skin model has a good antibacterial effect. The survival time of bacteria is prolonged, meanwhile, skin proliferation is promoted to a certain extent, and the real skin environment of the human body is further restored.